Clinical trials: Lung Hyperinflation
Pulmonary Disease, Chronic Obstructive
Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD.
- Trial name
- ACTIVATE (NCT02424344)
- Testing
- Aclidinium/Formoterol
- Where
- 26 sites in Canada, Germany and 2 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging
In this study the efficacy of Roflumilast in addition to LAMA/LABA therapy will be assessed using Functional Respiratory Imaging.
- Trial name
- NCT02451540
- Testing
- HRCT scan, Roflumilast
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- FLUIDDA nv
Chronic Obstructive Pulmonary Disease, COPD
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.
- Trial name
- NCT00108823
- Testing
- Roflumilast
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 550 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients
- Trial name
- NCT00636961
- Testing
- Indacaterol 300μg
- Where
- 3 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients
This is an early feasibility study to investigate whether transcutaneous electrical stimulation applied to the abdominal wall muscles synchronous with voluntary exhalation can be used to support ventilation and affect…
- Trial name
- NCT02035228
- Testing
- Abdominal Stimulation - low / early, Abdominal stimulation - low/late, Abdominal Stimulation - low/full
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Liberate Medical
Pulmonary Emphysema
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)
The purpose of this study is to demonstrate the safety and efficacy of AeriSeal System treatment plus optimal medical therapy compared in patients with advanced upper lobe predominant (ULP) heterogeneous emphysema.
- Trial name
- ASPIRE (NCT01449292)
- Testing
- Treatment plus Optimal Medical Therapy, Optimal Medical Therapy
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
A Study Comparing the Effects of Trimbow to Fostair in COPD
A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation…
- Trial name
- TRIFLOW (NCT03842904)
- Testing
- Trimbow pMDI, Fostair pMDI
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Medicines Evaluation Unit Ltd
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease.
- Trial name
- NCT04155047
- Testing
- Glyocopyrrolate Inhalation Solution administered by Magnair
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Phase IV O2 Consumption Study in COPD Patients.
A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after administration of Symbicort pMDI 160/4.5 μg.
- Trial name
- NCT02533505
- Testing
- Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
Primary objective of this observational study was to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) 18 microgram on the health-related quality of life and physical functioning in patients with…
- Trial name
- NCT02172521
- Testing
- Tiotropium bromide
- Volunteers
- 1,536 people
- Sponsor
- Boehringer Ingelheim
Emphysema
EASE Trial: Exhale Airway Stents for Emphysema
This is an international clinical research study evaluating the safety and effectiveness of a new procedure called airway bypass.
- Trial name
- EASE (NCT00391612)
- Testing
- Exhale® Drug-Eluting Stent
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 450 people
- Sponsor
- Broncus Technologies
Chronic Obstructive Pulmonary Disease
CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD
Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3-Way Cross-Over Study To Evaluate The Effect Of A Triple Combination Of Beclometasone Dipropionate And Formoterol Fumarate Plus Glycopyrronium (CHF5993)…
- Trial name
- TRIFORCE (NCT05097014)
- Testing
- CHF5993, CHF1535
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Emphysema or COPD
Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema
The goal of this clinical trial is to test the feasibility of an implant for severe emphysema in up to 30 participants at up to 5 study centers located in Europe and the United Kingdom.
- Trial name
- BREATHE-2 (NCT05949645)
- Testing
- Apreo Implant Group
- Where
- 3 sites in Austria, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Apreo Health, Inc.
COPD, Emphysema
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea…
- Trial name
- BREATHE-3 (NCT06891755)
- Testing
- Apreo BREATHE Airway Scaffold, Optimal Medical Management (OMM)
- Where
- 23 sites in United States, Austria and 3 more
- Volunteers
- 250 people
- Sponsor
- Apreo Health, Inc.
Emphysema or COPD, Emphysema
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.
- Conditions
- Emphysema or COPD, Emphysema, COPD
- Trial name
- IAB-2 (NCT07119229)
- Testing
- Implantable Artificial Bronchus
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pulmair Medical, Inc.
Emphysema
Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)
The objective of this study is to demonstrate the safety and performance of the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) in a population of patients with emphysema. The PneumRx, Inc.
- Trial name
- NCT01334307
- Testing
- Lung Volume Reduction Coil (LVRC) (PneumRx), Control
- Where
- 3 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Disease, Chronic Obstructive
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
Optimal clinical management in early stages of COPD is not established. Tiotropium has been shown to improve exercise tolerance during (CWR) cycle ergometry with GOLD stage II to IV COPD, improvements in constant speed treadmill…
- Trial name
- NCT01072396
- Testing
- Tiotropium
- Where
- 15 sites in United States, Canada
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD.
- Trial name
- NCT01533935
- Testing
- Tiotropium + Olodaterol, Tiotropium, Olodaterol
- Where
- 33 sites in United States, Argentina and 6 more
- Volunteers
- 291 people
- Sponsor
- Boehringer Ingelheim
Emphysema, Pulmonary, Emphysema or COPD
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe.
- Trial name
- CONVERT_II (NCT06035120)
- Testing
- AeriSeal System
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 200 people
- Sponsor
- Pulmonx Corporation
Air Trapping, Emphysema
Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in Emphysema
The objective of this study is to provide a regional, mechanistic characterization of pulmonary ventilation changes following treatment with the Apreo BREATHE System, using hyperpolarized ¹²⁹Xe MRI, in BREATHE-3 participants.
- Conditions
- Air Trapping, Emphysema, Hyperinflation
- Trial name
- BREATHE-Xe (NCT07896902)
- Testing
- Hyperpolarized Xenon MRI, Apreo BREATHE Airway Scaffold
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Apreo Health, Inc.